AI assistant
Sending…
Oruka Therapeutics, Inc. — Director's Dealing 2012
Feb 15, 2012
32280_dirs_2012-02-14_1d35630a-2529-42ca-ae0e-cfeea826d1ab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-02-10
Reporting Person: BREWER RICHARD B (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-02-10 | Option to Purchase Common Stock | $1.00 | A | 3500 | Acquired | 2022-02-10 | Common Stock (3500) | Direct |
| 2012-02-10 | Option to Purchase Common Stock | $1.00 | A | 3500 | Acquired | 2022-02-10 | Common Stock (3500) | Direct |
Footnotes
F1: The options vest in 12 equal monthly installments measured from 1/1/12. If the Reporting Person's service as a director of the Issuer terminates in connection with or at anytime following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
More from Oruka Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Interim / Quarterly Report
2026
May 13
Capital/Financing Update
2026
Apr 30
Capital/Financing Update
2026
Apr 27
Capital/Financing Update
2026
Apr 27
Regulatory Filings
2026
Apr 27
Capital/Financing Update
2026
Apr 21
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Major Shareholding Notification
2026
Mar 27